Qiagen (NYSE:QGEN) Price Target Raised to $60.00 at JPMorgan Chase & Co.

Qiagen (NYSE:QGEN) had its price target boosted by JPMorgan Chase & Co. from $55.00 to $60.00 in a research note published on Friday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

QGEN has been the topic of several other reports. Wall Street Zen lowered shares of Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. Citigroup lowered their target price on Qiagen from $55.40 to $55.00 and set a “neutral” rating on the stock in a research report on Friday. UBS Group reiterated a “neutral” rating on shares of Qiagen in a report on Wednesday, January 21st. Deutsche Bank Aktiengesellschaft lowered Qiagen from a “buy” rating to a “hold” rating and boosted their price target for the stock from $52.00 to $54.00 in a research report on Thursday, January 22nd. Finally, Robert W. Baird set a $53.00 target price on shares of Qiagen in a report on Friday. Four equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, Qiagen currently has a consensus rating of “Hold” and a consensus price target of $55.27.

Qiagen Stock Down 0.3%

Shares of Qiagen stock opened at $51.08 on Friday. The firm has a market cap of $10.79 billion, a PE ratio of 25.33, a P/E/G ratio of 2.57 and a beta of 0.67. The business’s 50 day simple moving average is $49.65 and its 200 day simple moving average is $49.67. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.30 and a current ratio of 2.60. Qiagen has a 52-week low of $39.61 and a 52-week high of $57.81.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. Qiagen had a return on equity of 14.82% and a net margin of 20.33%.The firm had revenue of $540.42 million during the quarter, compared to the consensus estimate of $528.53 million. During the same quarter in the prior year, the firm posted $0.61 EPS. The business’s revenue was up 3.6% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. On average, analysts predict that Qiagen will post 2.26 earnings per share for the current fiscal year.

Institutional Trading of Qiagen

Hedge funds and other institutional investors have recently bought and sold shares of the business. Massachusetts Financial Services Co. MA grew its position in shares of Qiagen by 1.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 24,205,881 shares of the company’s stock worth $1,088,538,000 after purchasing an additional 264,921 shares in the last quarter. Vanguard Group Inc. grew its position in Qiagen by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 9,542,944 shares of the company’s stock worth $433,871,000 after buying an additional 118,135 shares in the last quarter. Amundi increased its stake in Qiagen by 4.4% during the 3rd quarter. Amundi now owns 4,290,273 shares of the company’s stock worth $201,471,000 after acquiring an additional 181,509 shares during the period. Boston Partners acquired a new position in Qiagen in the 3rd quarter valued at $179,450,000. Finally, Norges Bank acquired a new position in Qiagen in the 2nd quarter valued at $158,728,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen News Summary

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: JPMorgan raised its price target to $60 and set an “overweight” rating, signaling ~17.5% upside from current levels. This analyst upgrade is a near-term bullish catalyst. Article Title
• Positive Sentiment: Unusually large options activity: traders bought ~40,639 call options (a ~4,600% increase vs. average), suggesting some investors are positioning for upside. (no article link provided)
• Positive Sentiment: Management reiterated a sales-growth target (at least ~5% sales growth for 2026), which supports topline momentum assumptions even as profitability is pressured. Article Title
• Neutral Sentiment: Citigroup trimmed its target slightly to $55 and moved to “neutral” — a modest calibration rather than a stark downgrade; this tempers but does not reverse bullish signals. Article Title Ticker Report
• Neutral Sentiment: Q4 results: EPS roughly in line ($0.62, vs. $0.61 consensus) and revenue modestly beat — evidence of steady demand but not a breakout. Zacks Earnings Article
• Neutral Sentiment: Full earnings materials and call transcript are available for deeper read‑throughs (slides, call transcript) — useful for investors assessing guidance drivers and margin details. Press Release Earnings Transcript
• Negative Sentiment: Guidance disappointed: Q1 EPS guidance (~$0.54) and FY‑2026 EPS (≈$2.50) were below Street consensus, which pressured sentiment as investors focus on margin recovery and near‑term profitability. Press Release
• Negative Sentiment: Margin contraction noted in coverage: analysts and news pieces flagged margin pressure and cautious tone on 2026, which was a primary reason the stock sold off despite the top‑line beat. Zacks Margin Article

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.